TKNO — Alpha Teknova, Inc.

Summary of Teknova Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $10.5 million, up 9% from $9.6 million in Q3 2024.
• Lab Essentials Revenue: $8.3 million, a 16% increase from $7.2 million in Q3 2024.
• Clinical Solutions Revenue: $1.7 million, down 13% from $2.0 million in Q3 2024.
• Gross Profit: $3.2 million, significantly improved from $0.1 million in Q3 2024.
• Gross Margin: 30.7%, up from 0.9% in Q3 2024, primarily due to the absence of prior nonrecurring charges.
• Net Loss: $4.3 million, or negative $0.08 per diluted share, improved from a net loss of $7.6 million, or negative $0.15 per diluted share, in Q3 2024.
• Adjusted EBITDA: Negative $1.6 million, improved from negative $2.2 million in Q3 2024.
• Cash Position: $22.1 million in cash and equivalents; total borrowings at $13.2 million.

2. Strategic Updates and Business Highlights

• Operational Efficiency: Investments in electronic batch records and automation are expected to enhance operational efficiency by 2026.
• Customer Base Expansion: Increased and diversified Clinical Solutions customer base, expected to drive revenue growth as therapies move toward commercialization.
• Product Performance: Continued strong performance in catalog products, with double-digit growth across various segments, including animal health and diagnostics.
• Acquisition Strategy: Actively pursuing tuck-in acquisitions to enhance capabilities and accelerate growth.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Reiterated guidance of $39 million to $42 million, with expectations to finish slightly below the midpoint due to softness in Clinical Solutions.
• 2026 Expectations: Anticipate modest growth in custom biopharma products and low double-digit growth in the remaining 75% of revenue.
• Gross Margin Target: Expected to remain in the low 30s for fiscal year 2025.
• Operating Expenses: Projected to be at least $8 million in Q4 2025, with plans for moderate increases in sales and marketing investments.

4. Bad News, Challenges, or Points of Concern

• Clinical Solutions Decline: Revenue from Clinical Solutions decreased due to lower average revenue per customer, highlighting volatility in this segment.
• Biotech Funding Environment: Ongoing delays in larger purchases from biopharma customers and uncertainty in the biotech funding landscape could hinder growth.
• Customer Acquisition Challenges: Although new customers are being onboarded, the company faces challenges from previous customers no longer in operation, impacting overall growth.

5. Notable Q&A Insights

• Customer Conversations: There is optimism regarding the impact of MFN pharma tariffs, but actual purchasing actions have not yet materialized.
• RUO+ Initiative: The initiative is performing well, providing flexibility for customers not ready for GMP, and is seen as a pathway to migrate them to GMP.
• Product Mix and Demand: The company is seeing consistent demand across its primary product lines, with particular interest in tools and diagnostics.
• Sales Force Strategy: Modest increases in the sales force are planned, with a focus on efficiency rather than significant headcount growth.

Overall, Teknova's Q3 2025 results reflect a solid performance driven by Lab Essentials, while challenges in the Clinical Solutions segment and the broader biotech funding environment present notable risks. The company remains optimistic about long-term growth and operational improvements.